Comment on FR Doc # 2026-10128

Summary: Pfizer Inc. opposes the proposed rule to make permanent the use-specific quota subcategories and the requirement to identify API suppliers nine months in advance. The company argues that these regulations fragment the supply chain, discourage dual sourcing, and interact poorly with existing inventory caps, potentially leading to drug shortages for essential sterile injectables.